Research programme: cancer therapeutics - Welichem Biotech

Drug Profile

Research programme: cancer therapeutics - Welichem Biotech

Alternative Names: WBI-2000 series; WBI-2100

Latest Information Update: 17 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Welichem Biotech
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 17 Mar 2008 Preclinical development is ongoing
  • 24 Jan 2007 Preclinical data added to the Cancer pharmacodynamics section
  • 27 Sep 2005 Welichem Biotech has selected WBI 2100 as the lead compound from the programem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top